{"id":"W1944300754","doi":"10.4049/jimmunol.181.1.776","title":"Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant","year":2008,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":245,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; York University; Cancer Research Institute; Ludwig Institute for Cancer Research; National Institute of Allergy and Infectious Diseases; Bill and Melinda Gates Foundation; Emerald Foundation; Burroughs Wellcome Fund","keywords":"Imiquimod; TLR7; Medicine; Adjuvant; Immunogenicity; Immunology; Peripheral blood mononuclear cell; Immune system; Melanoma; Cancer research; Innate immune system; Biology; Toll-like receptor","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007381581,0.0003439982,0.00082166,0.000340701,0.0005468701,0.000009009723,0.0007865966,0.0003051473,0.0003769862],"category_scores_gemma":[0.0001837444,0.0002071755,0.0001807265,0.0003359943,0.0006657294,0.0002617066,0.0001434385,0.0007098643,0.00004559198],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001025012,"about_ca_system_score_gemma":0.0004177932,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002184532,"about_ca_topic_score_gemma":0.000006321133,"domain_scores_codex":[0.996763,0.001312936,0.001140928,0.0001683016,0.0001272238,0.0004876435],"domain_scores_gemma":[0.9967668,0.0002632756,0.001629205,0.0006123763,0.0007085904,0.0000197244],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.02204886,0.0005798532,0.002718707,0.00001591364,0.001439337,0.00002350063,0.001655907,0.00007243178,0.9687037,0.0001482257,0.000077679,0.002515834],"study_design_scores_gemma":[0.01227042,0.01215587,0.1203888,0.0004303501,0.0003686508,0.00729379,0.00113826,0.000008625022,0.8416631,0.0001147163,0.003693544,0.000473868],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.975845,0.02230231,0.0005646524,0.000238082,0.0004997396,0.0004496706,0.00001371263,0.00001921548,0.00006763452],"genre_scores_gemma":[0.9972841,0.001753156,0.0002556619,0.00007022081,0.00002787875,0.000004765527,0.0000260155,0.00004838969,0.0005298458],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1270407,"threshold_uncertainty_score":0.844837,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009717852500198958,"score_gpt":0.2135990563724195,"score_spread":0.2038812038722206,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}